Skip to main content

ARCH Venture Fund IX, L.P.'s Form 4 filing

Lyell Immunopharma, Inc. (LYEL) · filed Mar 9, 2026

Accession no.
0001012975-26-000235
Filed
Mar 9, 2026, 4:36 PM ET
Trade date
Mar 6, 2026
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market purchases total $12.5M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
ARCH Venture Fund IX, L.P.CIK 000166630610% Owner
ARCH Venture Fund IX Overage, L.P.CIK 000166630710% Owner
ARCH Venture Partners IX Overage, L.P.CIK 000172317210% Owner
ARCH Venture Partners IX, L.P.CIK 000172317310% Owner
ARCH Venture Partners IX, LLCCIK 000172317410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 6, 2026Common StockPPurchaseAcquired+488,090$25.61+$12,499,984.91,426,528IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

This Form 4 is one of two reports relating to the same transaction being filed jointly by ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., Keith Crandell, Robert Nelsen, Kristina Burow, Steven Gillis, Paul Berns, Clinton Bybee, ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P. and ARCH Venture Fund IX Overage, L.P.

Read the full filing on SEC EDGAR (opens in a new tab)